Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | The role of enfortumab vedotin in urothelial cancer treatment

Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center in Houston, TX, highlights the promising role of enfortumab vedotin in the long-term treatment of urothelial cancer. She references the Phase III EV-302 (NCT04223856) trial of enfortumab vedotin and pembrolizumab versus chemotherapy alone in untreated locally advanced or metastatic urothelial carcinoma. The study demonstrated that enfortumab vedotin, in combination with pembrolizumab, resulted in objective responses in over 60% of patients, regardless of platinum eligibility. Moreover, the trial showed an improvement in overall survival (OS) compared to chemotherapy alone. Dr Siefker-Radtke emphasizes the significant impact of this combination therapy on extending median life expectancy, although more follow-up data is needed to determine the ultimate median survival. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.